Neurology

Aducanumab, lecanemab, and donanemab are novel monoclonal antibodies designed to slow disease progression and hopefully have a positive impact in the field of Alzheimer disease management.

Choice of therapy should be selected based on patient needs and conditions.

Intravenous immunoglobulin found to provide fast and long-lasting relief for COVID-19-related neurological conditions, although investigators are still uncovering the pathology of many of these conditions.

This disease can, at the very least, help researchers to “identify” the floodgates to definitive tests and therapies for complex psychological and neurological diseases, expert says.

In clinical trials, lecanemab showed a reduction of amyloid beta plaque in patients with Alzheimer disease.

Testosterone may protect the brain against dementia pathology, but the association has not been proven.

Infections were associated with a 1.49-fold increase in the rate of dementia in both the short- and long-term rates, however, the increases were greater in the short term.

Symptoms of dementia can be difficult to differentiate from typical age-related behavior changes and other common and potentially curable conditions.

One IVIG product showed overall improvement in neuroprotection, including alleviating cognitive decline and ameliorating AB deposition in Alzheimer disease.

Pharmacists can make clinical recommendations tailored to patients’ individual needs.

Heart health may influence long-term brain health as early as middle age.

This social determinant of health could have the same level of negative impact on health as the experience of racism, poverty, or low education.

The drug can now be tested for safety, tolerability, and efficacy in a phase 1 study.

During the phase 1b/2 trials, CAR T-cell therapy demonstrated significant and clinical survival benefits.

Relapses of MIS-C occurred in 2 patients due to rapid tapering of corticosteroids at 2 weeks instead of the standard protocol of 4 to 6 weeks.

Advancements in the development of amyloid-targeting monoclonal antibodies show promise for treating Alzheimer disease, but there have been concerns around cost, adverse reactions, and inequity of care for marginalized patients.

Pharmacists play a key role in the management of modern monoclonal antibody treatments for Alzheimer disease.

Patient retraces her treatment journey from diagnosis through treatment for glioblastoma.

New anti-amyloid monoclonal antibody drugs for Alzheimer disease have produced encouraging results in targeting the accumulation of amyloid beta plaques; however, questions remain regarding the risk-benefit profile and cost implications.

Major pharmacogenomics organizations continue to recognize the potential relevance of pharmacogenomics for psychiatric medication management, mainly due to its effects on pharmacokinetics.

Idiopathic intracranial hypertension was previously considered a rare condition, however, its prevalence is increasing in parallel with obesity in patient populations.

Mobile apps can help consumers acquire medications, but few help with adherence beyond automatic refills or medication synchronization.

Participants were able to stop treatment after achieving amyloid plaque clearance and experience lasting results.

Study suggests supplemental oxygen may improve cognitive functions that are vital in motor learning, which can be important for people with neurological conditions or trauma.

Studies consistently demonstrate the pivotal involvement of neuropeptide calcitonin gene related peptide release in migraine onset.

Lecanemab-irmb is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer disease.

The safety and efficacy of long-term benzodiazepine use beyond the recommended timeframe is not well understood.

The blood pressure drug could provide relief for veterans and service members suffering from traumatic brain injuries.

Despite prior studies showing less brain injury biomarkers in patients with targeted mild hypercapnia, findings from a new trial suggest it does not improve neurological outcomes at 6 months.

Galcanezumab-gnlm (Emgality; Eli Lilly and Company) did not demonstrate superiority to rimegepant orally disintegrating tablet (Nurtec ODT) on the percentage of individuals achieving a 50% or greater reduction in monthly migraine headache days.